Ultra-early in-cath lab evolocumab achieves rapid lipid target attainment and lipid quality improvement in acute coronary syndrome: a real-world propensity score-matched study [PDF]
Frontiers in Cardiovascular MedicineBackgroundCurrent guidelines mandate stringent low-density lipoprotein cholesterol (LDL-C) control for patients with acute coronary syndrome (ACS). However, real-world evidence regarding the ultra-early, in-cath lab initiation of PCSK9 inhibitors and ...
Yufeng Jiang +6 more
doaj +2 more sources
Effect of Evolocumab on Lipoprotein Particles [PDF]
The American Journal of Cardiology, 2018 The level of low-density lipoprotein cholesterol (LDL-C) reflects the cholesterol carried mainly by low-density lipoprotein particles (LDL-P). LDL-C, however, does not always correlate with LDL-P because of the variable amounts of cholesterol per particle.
Peter P. Toth +9 more
core +5 more sources
Use of Negative Control Outcomes to Assess Cohort Comparability Among Evolocumab Initiators: A Real-World Database Study [PDF]
Clinical EpidemiologyYue Zou,1,* Cheng Qian,1,* Jiamei Liu,1 Yin Liu,1 Liming Zhao,1 Xuxiao Ye,2 Zhenna Huang,2 Jeff L Lange,3 Nafeesa Dhalwani,3 Fan Yang,1 Zizhao Zhang,4 Kangyin Chen,4 Hao Zhang,4 Jifang Zhou11School of International Pharmaceutical Business,
Zou Y +13 more
doaj +2 more sources
Perfil clínico de los pacientes tratados con evolocumab en unidades hospitalarias de nefrología en España (RETOSS-NEFRO) [PDF]
Nefrología, 2022 Resumen: Antecedentes y objetivo: Describir las características clínicas de los pacientes tratados con evolocumab, las razones del inicio de la terapia y los efectos del tratamiento en la fase inicial de disponibilidad de evolocumab en las unidades de ...
Marian Goicoechea +15 more
doaj +2 more sources
Patient Preference and Adherence, 2018 Constantine E Kosmas,1 Delia Silverio,2 Julio Ovalle,2 Peter D Montan,2 Eliscer Guzman3 1Division of Cardiology, Department of Medicine, Mount Sinai Hospital, New York, NY, USA; 2Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA; 3Division ...
Kosmas CE +4 more
doaj +1 more source
Exploratory observational study with Two-year outcomes of early in-hospital evolocumab in acute coronary syndrome patients undergoing coronary artery bypass grafting [PDF]
Frontiers in Cardiovascular MedicineAimsPatients with acute coronary syndrome (ACS) who require coronary artery bypass grafting (CABG) remain at very high ischemic risk due to diffuse native disease and vein graft vulnerability.
Giuseppe Nasso +22 more
doaj +2 more sources
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
Drug Design, Development and Therapy, 2017 Dave L Dixon,1 Leo F Buckley,1 Cory R Trankle,2 Dinesh Kadariya,3 Antonio Abbate2 1Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, 2Pauley Heart Center, 3Department of Internal Medicine, School of Medicine, Virginia Commonwealth ...
Dixon DL +4 more
doaj +1 more source
Nefrología (English Edition), 2022 Background and objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of Spain.
Marian Goicoechea +15 more
doaj +2 more sources
Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study [PDF]
Therapeutic Advances in Cardiovascular DiseaseAims: The HEYMANS study observed patients receiving evolocumab as part of routine clinical hyperlipidemia management. It was designed to capture data on clinical parameters relevant to health authorities and physicians. Methods: This was a European multi-
Isabella Sudano +7 more
doaj +2 more sources
Upsala Journal of Medical SciencesBackground: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials.
Maria K. Svensson +7 more
doaj +2 more sources